Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home.

ABSTRACT: Advanced age at diagnosis, comorbidities and invalidating symptoms can debilitate multiple myeloma (MM) and AL amyloidosis (AL) patients, potentially precluding access to optimal therapy. The Associazione Italiana contro le Leucemie, Linfomi e Mieloma (AIL) has been providing home care to hematological patients in Italy since 1993. Between 2014 and 2023, 83 MM and AL patients received home infusion therapy through AIL in Bologna. Half were newly diagnosed, and half had undergone 1-7 prior lines of therapy. The median age was 79 years and 56% of patients had a performance status ≥ 2. The most frequently administered drugs included bortezomib (82%), daratumumab (14%), and bendamustine (9%). During the median 116-day therapy duration (range 1-750), patients received a median of 12 drug admini

SUBMITTER: Bigi F 

PROVIDER: S-EPMC12116699 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature